Trial Profile
A randomised, cross-over, open label study to compare the effect of the SGLT2 inhibitor luseogliflozin with that of the dipeptidyl peptidase-4 inhibitor sitagliptin on hepatic fat deposition
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Mar 2016
Price :
$35
*
At a glance
- Drugs Luseogliflozin (Primary) ; Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 22 Mar 2016 New trial record